Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Pharma Equity Group A/S Board/Management Information 2023

Jun 15, 2023

3425_iss_2023-06-15_1c2a0a93-d13b-44e0-a121-98d5b34ab0d7.html

Board/Management Information

Open in viewer

Opens in your device viewer

Changes to the Board of Directors in Pharma Equity Group 

Changes to the Board of Directors in Pharma Equity Group

15 June 2023 

Announcement no. 35 

Changes to the Board of Directors in Pharma Equity Group 

Today, the company has received notice that the Chairman of the Board of Directors, Peter Mørch Eriksen and Board Member Ole Larsen have decided to resign from the Board with immediate effect.  

The Board has thereafter constituted itself with Christian Vinding Thomsen as Chairman of the Board of Directors. 

For further information, please contact:     

Christian Vinding Thomsen, Chairman of the Board of Directors of Pharma Equity Group A/S, phone: 2622 7222 

Thomas Kaas Selsø, CEO of Pharma Equity Group A/S, phone: 40 22 21 14 

About Pharma Equity Group A/S  

Pharma Equity Group A/S is a listed company on the Nasdaq Copenhagen Stock Exchange, with a focus on early investment in innovative life science companies (in or before phase 2) that develop technologies and therapies that have the potential to improve human health and quality of life.   

Pharma Equity Group A/S portfolio currently includes Reponex Pharmaceuticals A/S. Reponex Pharmaceuticals A/S is a clinical-stage biopharmaceutical company dedicated to the development of novel, effective treatments for diseases that have significant patient and social impact.